EGRIFTA
LOE Approachingtesamorelin
BLASUBCUTANEOUSPOWDER
Approved
Nov 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
EGRIFTA (tesamorelin) is vitro, tesamorelin binds and stimulates human grf receptors with similar potency as the endogenous grf [see clinical pharmacology ()]. First approved in 2010.
Drug data last refreshed 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EGRIFTA (tesamorelin) is a synthetic analog of growth hormone-releasing hormone (GHRH) administered subcutaneously as a powder for reconstitution. It treats HIV-associated lipodystrophy by stimulating endogenous GH release, which exerts anabolic and lipolytic effects across multiple tissue types. The mechanism reduces visceral adiposity and metabolic complications in HIV-infected patients.
LOE Approaching
Product is approaching end of lifecycle with moderate competitive pressure (30/100), signaling a transition phase requiring focus on retention and cost management.
Mechanism of Action
vitro, tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF [see Clinical Pharmacology ()]. Growth hormone-releasing factor (GHRF), also known as growth hormone-releasing hormone (GHRH), is a hypothalamic peptide that acts on the pituitary somatotroph…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV
Started Jul 2025
100 enrolled
HIV-1-infectionFrailtyImpaired Physical Function+2 more
Tesamorelin to Improve Functional Outcomes After Peripheral Nerve Injury
Started Jun 2018
36 enrolled
Peripheral Nerve Injuries
Tesamorelin Effects on Liver Fat and Histology in HIV
Started Jul 2015
61 enrolled
Human Immunodeficiency Virus (HIV)Nonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis (NASH)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.